Deltex expects US approval for updated Doppler monitor
This article was originally published in Clinica
UK company Deltex Medical Holdings expects to receive US FDA approval in June for its updated transoesophageal Doppler monitor, CardioQ, which uses a disposable probe to measure cardiac output during and after an operation.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.